BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35544458)

  • 41. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
    Balasundaram N; Ganesan S; Chendamarai E; Palani HK; Venkatraman A; Alex AA; David S; Kumar SP; Radhakrishnan NR; Yasar M; Krishna S; Korula A; Kulkarni U; Janet NB; Balasubramanian P; Mathews V
    Blood Adv; 2022 Jan; 6(2):652-663. PubMed ID: 34625794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute myeloid leukemia with NUP98::RARG resembling acute promyelocytic leukemia accompanying ARID1B gene mutation.
    Wu D; Gao R
    Hematology; 2023 Dec; 28(1):2227495. PubMed ID: 37387408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
    Nagai S; Takahashi T; Kurokawa M
    Curr Stem Cell Res Ther; 2010 Dec; 5(4):372-8. PubMed ID: 20528759
    [TBL] [Abstract][Full Text] [Related]  

  • 45. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Xu LW; Su YZ; Tao HF
    Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia.
    Coccaro N; Zagaria A; Orsini P; Anelli L; Tota G; Casieri P; Impera L; Minervini A; Minervini CF; Cumbo C; Parciante E; Mestice A; Delia M; Brunetti C; Specchia G; Albano F
    Hum Pathol; 2018 Oct; 80():82-86. PubMed ID: 29530751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
    Chen L; Wang J; Hu X; Xu X
    Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What is the standard regimen for patients with acute promyelocytic leukemia?
    Lo-Coco F; Cicconi L
    Curr Hematol Malig Rep; 2014 Jun; 9(2):138-43. PubMed ID: 24729066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
    Tang Y; Wang Y; Hu L; Meng F; Xu D; Wan K; Huang L; Li C; Zhou J
    Int J Clin Exp Pathol; 2015; 8(11):15294-300. PubMed ID: 26823883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
    Tallman M; Lo-Coco F; Barnes G; Kruse M; Wildner R; Martin M; Mueller U; Tang B
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):771-7. PubMed ID: 26361645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute Promyelocytic Leukemia with del(6)(p22) and Atypical bcr2 PML::RARA Fusion Transcript: A Case Report.
    Lauricella C; Greco R; Mancini V; Motta V; Ciraolo A; De Canal G; De Paoli E; Paglino G; Guido V; Bonoldi E; Veronese S; Soriani S
    Acta Haematol; 2023; 146(1):58-64. PubMed ID: 36198282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
    Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
    Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
    Shen Y; Fu YK; Zhu YM; Lou YJ; Gu ZH; Shi JY; Chen B; Chen C; Zhu HH; Hu J; Zhao WL; Mi JQ; Chen L; Zhu HM; Shen ZX; Jin J; Wang ZY; Li JM; Chen Z; Chen SJ
    EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
    Ohnishi K
    Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel NUP98-JADE2 fusion in a patient with acute myeloid leukemia resembling acute promyelocytic leukemia.
    Cheng CK; Chan HY; Yung YL; Wan TSK; Leung AWK; Li CK; Tian K; Chan NPH; Cheung JS; Ng MHL
    Blood Adv; 2022 Jan; 6(2):410-415. PubMed ID: 34673934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
    Nitto T; Sawaki K
    J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
    Wang L; Yan X; He J
    Medicine (Baltimore); 2020 Oct; 99(43):e22923. PubMed ID: 33120845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
    Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
    Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.